Topic: antiviral therapy

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

​​​​​​​The week’s biotech news included a map of the human lung that could aid asthma drug development and a compound that thwarts rhinoviruses like colds.

A combination of Viracta Therapeutics' nanatinostat and an antiviral drug produced a 58% response rate in an early trial.

BiomX raised $32 million for preclinical development of its customized phage cocktail therapies aimed at eradicating the bacteria behind IBD and acne.

Chimerix announced its president and CEO, M. Michelle Berrey, has resigned and is being replaced by a triumvirate of senior company officers.

The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine. 

New insights into the antiviral gene RSAD2 could be used to create new therapies to treat Zika, dengue and other flaviviruses.

Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.

Ansun BioPharma raised $85 million in series A financing and plans to use the funds for an upcoming phase 3 trial of its DAS181 antiviral medication.

Researchers at Imperial College London believe they’ve found a way to block multiple strains of the flu by targeting a protein it needs to survive.